High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients.
The effect of High-Dose Methylprednisolone (HD-MP) treatment on Peripheral Blood (PB) and Cerebrospinal Fluid (CSF) immune parameters was investigated in 9 patients with relapsing-progressive Multiple Sclerosis (MS). Short-time effects included reduction of the percentage of CD3+, CD4+ and CD4+CD45RA+ PB lymphocytes and increase in CD3-CD56+ cells. At the end of the treatment, only increase in PB CD19+ and in CSF CD8+, CD8+CD28+ and decrease of CSF CD4+CD45RA- and serum IL2R levels were observed. No changes in CD11a+CD4+, CD18+CD14+ PB cells were observed after treatment. The results further stress the complex and multifaceted action of HD-MP on immune parameters.
Dufour
A
A
Istituto Nazionale Neurologico, C. Besta, Milano, Italy.
Salmaggi
A
A
La Mantia
L
L
Eoli
M
M
Nespolo
A
A
Milanese
C
C
D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016827:CD8 Antigens / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000276:immunology / Q000378:metabolism; D002555:Cerebrospinal Fluid / Q000166:cytology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007376:Interleukin-2 / Q000378:metabolism; D007958:Leukocyte Count / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy / Q000276:immunology*
D016827:CD8 Antigens; D015815:Cell Adhesion Molecules; D007074:Immunoglobulin G; D007376:Interleukin-2; D008775:Methylprednisolone